A Message from Our CEO on Veterans Day
On this Veterans Day, we want to express our sincere gratitude and appreciation for the brave individuals who have served and sacrificed for our country. We also want to use today to raise awareness about the unique challenges faced by veterans when it comes to increased risk of developing melanoma,...
Melanoma Risk in the Military Community
By Renee Orcione, MRA Digital Engagement & Communications Manager | 9 November 2023 In News, Prevention, Science, Treatment
Ahead of Veterans Day, the Melanoma Research Alliance (MRA) wishes to recognize the brave individuals who have served and sacrificed for our country. As the largest private nonprofit funder of melanoma research worldwide, we are keenly aware of the important intersection between military service and melanoma.
What Veteran's Day Means to the MRA Team
In observation of Veteran's Day - November 11 - we asked the MRA team to create short videos explaining what the day means for them and what they want Veterans and other military personnel to know about their risk for melanoma, other skin cancers, and the importance of sun safety.
What Melanoma Patients Need to Know about Hepzato Kit
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 23 October 2023 In News, Science, Treatment
You may have heard of Hepzato Kit, also known as Liver-Directed Melphalan, the first liver-directed therapy available for patients with metastatic uveal melanoma who have liver metastases that cannot be surgically removed.
MRA Statement on Expanded Approval of Nivolumab to Patients with Stage 2 Disease
The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, welcomes the U.S. Food and Drug Administration (FDA) decision to expand eligibility of Bristol Myers Squibb’s Opdivo (nivolumab) to include patients with completely resected Stage IIB and IIC melanoma.
A Message from Our CEO on Rare Cancer Day
Acral, mucosal, pediatric, and uveal melanomas – what we collectively call rare melanomas – represent an area of profound unmet medical need. Learn what MRA is doing to accelerate research focused on rare melanomas.
Dr. Hussein Tawbi: Opdualag Clinical Trial Updates
In March of 2022, the melanoma community celebrated the FDA approval of nivolumab + relatlimab (brand name Opdualag), a new treatment for patients with metastatic melanoma that combines two different immunotherapies, nivolumab and relatlimab, into one medicine.
MRA Statement on FDA Approval of Hepzato Kit for Patients with Uveal Melanoma with Liver Metastases
The Melanoma Research Alliance (MRA) released the following statements from MRA Chief Science Officer Joan Levy, PhD and MRA Chief Executive Officer Marc Hurlbert, PhD on the Food & Drug Administration approval of Hepzato Kit for patients with uveal melanoma with liver metastases that cannot be surgically removed.
MRA's Latest Research Report: Reaching for the Stars
Each year, MRA convenes global thought leaders from across the melanoma research community to exchange ideas, report on scientiﬁc successes and challenges, and network and forge new collaborations.
Reflecting on a Decade of Progress and Future Heights in Melanoma
If you told Dr. Jedd Wolchok at the start of his oncology career what melanoma research would look like today, he likely wouldn’t believe you. Wolchok, now a world-renowned medical oncologist and Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, originally faced an alternate...